Proteomics

Dataset Information

0

Omics Reveal Far Reaching Effects of Verapamil Treatment in Subjects with Type 1 Diabetes


ABSTRACT: Proteomic data from recent onset T1D patients treated with verapamil where significant extension of the honeymoon phase was observed. Samples were depleted with MARS Hu-14 column, digested with trypsin, labeled with 11-plex TMT, then analyzed by LC-MS/MS. Data was searched with MS-GF+ using PNNL's DMS Processing pipeline. TMT data was extracted using PlexedPiper.

INSTRUMENT(S): Orbitrap Fusion Lumos

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Wei-Jun Qian  

PROVIDER: MSV000087598 | MassIVE | Wed Jun 09 14:14:00 BST 2021

SECONDARY ACCESSION(S): PXD026601

REPOSITORIES: MassIVE

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1
altmetric image

Publications


Currently, no oral medications are available for type 1 diabetes (T1D). While our recent randomized placebo-controlled T1D trial revealed that oral verapamil had short-term beneficial effects, their duration and underlying mechanisms remained elusive. Now, our global T1D serum proteomics analysis identified chromogranin A (CHGA), a T1D-autoantigen, as the top protein altered by verapamil and as a potential therapeutic marker and revealed that verapamil normalizes serum CHGA levels and reverses T  ...[more]

Similar Datasets

| MSV000088053 | MassIVE
2022-08-18 | MSV000090157 | MassIVE
2023-11-21 | MSV000093454 | MassIVE
2019-11-01 | MSV000084528 | MassIVE
2021-05-29 | MSV000087543 | MassIVE
2020-04-16 | MSV000085298 | MassIVE
2020-08-31 | MSV000086049 | MassIVE
| MSV000086144 | MassIVE
2020-12-31 | MSV000086652 | MassIVE
2021-04-28 | MSV000087330 | MassIVE